- Conditions
- Neurotrophic Keratitis
- Interventions
- Cenegermin-Bkbj
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 1,659
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Single Ventricle Physiology
- Interventions
- Passive range of motion (ROM) exercise
- Other
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas • Salt Lake City, Utah
- Conditions
- Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer
- Interventions
- Abiraterone acetate, Apalutamide, Enzalutamide
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 9 more
- Conditions
- Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
- Interventions
- TransCon hGH
- Drug
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
- Conditions
- Connective Tissue Disorders, Osteogenesis Imperfecta, Bone Diseases, Metabolic, Melorheostosis
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Up to 70 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Language Development, Language, Child, Early Intervention
- Interventions
- Duet Language Intervention Modules
- Behavioral
- Lead sponsor
- Temple University
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypothyroidism
- Interventions
- Growth hormone, Growth hormone treatment and puberty
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
- Interventions
- TAS6417
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
- Interventions
- Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 952 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
- Conditions
- Breast Cancer
- Interventions
- erlotinib hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Early-Onset Scoliosis Deformity of Spine
- Interventions
- Growth-sparing instrumentation and titanium levels
- Combination Product
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 5 Years to 15 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Growth
- Interventions
- Cow's milk protein infant formula, Partially hydrolyzed protein infant formula
- Other
- Lead sponsor
- Mead Johnson Nutrition
- Industry
- Eligibility
- 10 Days to 14 Days
- Enrollment
- 244 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 10 more
- Conditions
- Cerebroplacental Ratio
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- New Brunswick, New Jersey • Sewell, New Jersey • Flushing, New York + 2 more
- Conditions
- Very Low Birth Weight Infant, Weight Gain, Feeding Disorder Neonatal
- Interventions
- Treatment Guardian Milk Warmer (Medela TM), Control
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 1 Day to 30 Days
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Macular Disease
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska
- Conditions
- Hypertension
- Interventions
- SPP100
- Drug
- Lead sponsor
- LXO Group
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Dalton, Georgia + 7 more
- Conditions
- Prematurity
- Interventions
- Amino acids
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- Up to 18 Hours
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Obesity
- Interventions
- recombinant human growth hormone (rhGH), Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years to 21 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg, Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg, Ixabepilone + Lapatinib + Capecitabine
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Sleep Apnea Syndromes
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,685 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab (drug), Herceptin (drug)
- Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 18
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 14 more
- Conditions
- Hypochondroplasia
- Interventions
- Not listed
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 30 Months to 16 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
- Interventions
- Osimertinib, Osimertinib + Chemotherapy
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more
- Conditions
- Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
- Interventions
- Ameluz 10% Topical Gel, Protoporphyrin IX
- Drug · Device
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire